Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.57 |
| ▸ | CTSK | P43235 | 2/20 | 0.57 |
| ▸ | P2RX7 | Q99572 | 15/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29542921 | 1.00 | CTSS (0.57) | CTSSCTSKP2RX7PARP1LMNA | |
| Hydrochloric Acid SCHEMBL27843312 | 0.98 | CTSS (0.56) | CTSSCTSKP2RX7PARP1LMNA | |
| SCHEMBL28311763 | 0.85 | CTSS (0.55) | CTSSCTSKP2RX7LMNAGAA | |
| SCHEMBL422330 | 0.83 | TSHR (0.57) | CTSSCTSKP2RX7LMNAGAA | |
| SCHEMBL16127683 | 0.83 | CTSS (0.57) | CTSSCTSKP2RX7LMNAGAA | |
| SCHEMBL108509 | 0.83 | CTSS (0.54) | CTSSCTSKP2RX7LMNAGAA | |
| SCHEMBL9524633 | 0.81 | CTSS (0.56) | CTSSCTSKP2RX7LMNAGAA | |
| SCHEMBL9637140 | 0.81 | CTSS (0.52) | CTSSCTSKP2RX7LMNAGAA | |
| SCHEMBL3185133 | 0.81 | CTSS (0.52) | CTSSCTSKP2RX7LMNAGAA | |
| Hydrochloric Acid SCHEMBL2990630 | 0.81 | TSHR (0.55) | CTSSCTSKP2RX7LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2804865-B1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-23 | — | — | EP | claimed |
| CN-103936719-A | Preparation method and application of benzimidazoles derivatives | UNIV CHINA PHARMA | 2014-07-23 | — | — | CN | claimed |
| CN-103087054-A | 4-pyridyl phenyl ether compounds, and preparation method and application thereof | UNIV SHANDONG | 2013-05-08 | — | — | CN | claimed |
| CN-110003200-B | P2X7 modulators | 詹森药业有限公司 | 2021-11-26 | — | — | CN | disclosed |
| WO-2020223548-A1 | INHIBITING USP36 | INTEGRAL EARLY DISCOVERY, INC. (US) | 2020-11-05 | — | — | WO | disclosed |
| US-9409917-B2 | Heterocyclic amide derivatives as P2X7 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-08-09 | — | — | US | disclosed |
| US-20150025075-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-01-22 | — | — | US | disclosed |
| CN-103936719-A | Preparation method and application of benzimidazoles derivatives | UNIV CHINA PHARMA | 2014-07-23 | — | — | CN | disclosed |
| CN-103087054-A | 4-pyridyl phenyl ether compounds, and preparation method and application thereof | UNIV SHANDONG | 2013-05-08 | — | — | CN | disclosed |
| CN-101684118-B | Use of tricyclic compounds as glycine transport inhibitors | SANOFI AVENTIS | 2013-04-10 | — | — | CN | disclosed |
| CN-102256975-A | New polymorphic forms of azabicyclo-trifluoromethylbenzamide derivatives | SANOFI AVENTIS | 2011-11-23 | — | — | CN | disclosed |
| CN-101684118-A | Use of tricyclic compounds as glycine transport inhibitors | SANOFI AVENTIS | 2010-03-31 | — | — | CN | disclosed |
| US-20100016374-A1 | Compounds Which Inhibit the Glycine Transporter and Uses Thereof | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| EP-2001831-A2 | COMPOUNDS WHICH INHIBIT THE GLYCINE TRANSPORTER AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2008-12-17 | — | — | EP | disclosed |
| WO-2008018639-A2 | GLYCINE TRANSPORTER INHIBITOR | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-02-14 | — | — | WO | disclosed |
| WO-2007113309-A2 | COMPOUNDS WHICH INHIBIT THE GLYCINE TRANSPORTER AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
| CN-1882587-A | Use of tricyclic compounds as glycine transport inhibitors | SANOFI AVENTIS (FR) | 2006-12-20 | — | — | CN | disclosed |
| US-20060211739-A1 | Use of selective P2X7 receptor antagonists | ABBOTT LABORATORIES | 2006-09-21 | — | — | US | disclosed |
| WO-2006086229-A1 | THE USE OF SELECTIVE P2X7 RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025075-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX1, P2RX3 | CTSS 2366/4885CTSK 2149/4885P2RX7 1/4885 |
| US-20060211739-A1 | Use of selective P2X7 receptor antagonists | P2RX1, P2RX3, P2RX7 | CTSS 2382/4885CTSK 2291/4885P2RX7 3/4885 |
| US-20100016374-A1 | Compounds Which Inhibit the Glycine Transporter and Uses Thereof | SLC6A5, SLC6A9, SLC6A19 | CTSS 4252/4885CTSK 4276/4885P2RX7 2181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.